A recent report by the Centre for Health Technology Assessment (Centro de Evaluación de Tecnologías Sanitarias, CETSA), part of the ISALUD University, Buenos Aires, Argentina, states that the costs of highly complex treatments could be lowered if biosimilar medicines are included in the national system.

CETSA from ISALUD University is a non-profit organization that was born from the will of different actors, such as representatives of social works to find a place for training and consultation within an academic environment, as is the ISALUD University, and has years of experience in the field of public health in Argentina. Health technology assessment and medical education are the core areas of CETSA. Its main mission is to form and organize programmatically a Health Technology Assessment team.

According to CETSA, if these drugs are used in the Argentine health system, savings of US$12.6 million would be achieved. The introduction of these therapeutics in international markets resulted in estimated savings of Euros 10 billion between 2016 and 2020 in five European countries (France, Germany, Italy, Spain and the UK). Experience in Europe suggests that by optimizing health budgets, health systems have more funds to invest in innovation and other health areas such as diagnostics, prevention, technologies, training of their professionals, and expanding the supply and accessibility of services for patients and health professionals.

The Director of CETSA-ISALUD and consultant in prioritization of health interventions at the Inter-American Development Bank (IDB), Natalia Jorgensen, explained that communication and education on biosimilars is a fundamental aspect to generate the necessary confidence throughout the value chain. The director explained that in Argentina the introduction of biosimilars is more difficult because the health system is very fragmented and there is no national policy on biosimilars, so their introduction depends on each of the funders, including, for example, the decision taken by each of the 290 national social works (NGOs), the 24 provincial social works and the public sector. Thus, the process is slower and the economic impact one observes is likely to be smaller.

Editor’s comment
Readers interested to learn more about biosimilars in other countries are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Biosimilars patent litigation in the EU and the US: a comparative strategic overview

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper in Spanish and/or English about biosimilars to GaBI Journal – an independent, peer reviewed academic journal – please submit your manuscript here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
1.9 – CiteScoreTracker 2021 (Last updated on 4 August 2021)

Submit a manuscript to GaBI Journal

Related articles
GABiC proposes the use of biosimilars as strategy for innovation and sustainability

Country scorecards show biosimilar sustainability

Optimizing the benefits of biosimilars for society

EC workshop on biosimilars focusses on sustainability

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.